206 related articles for article (PubMed ID: 36362239)
1. EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC.
Chang ZT; Chan TM; Wu CE
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362239
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
3. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
[TBL] [Abstract][Full Text] [Related]
4. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
5. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
[TBL] [Abstract][Full Text] [Related]
7. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
9. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
[TBL] [Abstract][Full Text] [Related]
10. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report.
Fang YF; Liu PC
Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927
[TBL] [Abstract][Full Text] [Related]
11. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
Iwama E; Sakai K; Azuma K; Harada D; Nosaki K; Hotta K; Nishio M; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Cancer Sci; 2018 Dec; 109(12):3921-3933. PubMed ID: 30289575
[TBL] [Abstract][Full Text] [Related]
12. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
13. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
16. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
[TBL] [Abstract][Full Text] [Related]
17. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.
Ding PN; Becker T; Bray V; Chua W; Ma Y; Xu B; Lynch D; de Souza P; Roberts T
Thorac Cancer; 2019 Oct; 10(10):1879-1884. PubMed ID: 31414729
[TBL] [Abstract][Full Text] [Related]
18. Lung adenocarcinoma in a patient with a cis EGFR L858R-K860I doublet mutation identified using NGS-based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib.
Onozawa H; Saito H; Sunami K; Kubo T; Yamamoto N; Kasajima R; Ohtsu T; Hiroshima Y; Kanamori H; Yokose T; Miyagi Y
Thorac Cancer; 2020 Dec; 11(12):3599-3604. PubMed ID: 33034420
[TBL] [Abstract][Full Text] [Related]
19. Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma.
Kim HS; Sung JS; Yang SJ; Kwon NJ; Jin L; Kim ST; Park KH; Shin SW; Kim HK; Kang JH; Kim JO; Park JY; Choi JE; Yoon H; Park CK; Yang KS; Seo JS; Kim YH
PLoS One; 2013; 8(12):e81975. PubMed ID: 24376508
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
